Printer Friendly

LIDAK PHARMACEUTICALS REPORTS RESULTS

 LIDAK PHARMACEUTICALS REPORTS RESULTS
 LA JOLLA, Calif., Feb. 14 /PRNewswire/ -- LIDAK Pharmaceuticals


(NASDAQ: LDAKU, LDAKA) today reported a net loss of $538,815, or $.07 per share, on revenues of $119,600 for the first quarter ended Dec. 31, 1991. For the quarter ended Dec. 31, 1990, the company reported a net loss of $463,112, or $.06 per share, on revenues of $127,400.
 LIDAK PHARMACEUTICALS
 Consolidated Income Statement
 (Unaudited)
 For the quarter ended Dec. 31,
 1991 1990
 Revenue $119,600 $127,400
 Net loss ($538,815) ($463,112)
 Net loss per share ($.07) ($.06)
 Weighted average
 shares outstanding 7,461,271 7,345,398
 -0- 2/14/92
 /CONTACT: Michael H. Lorber, VP & CFO of LIDAK Pharmaceuticals, 619-558-0364/
 (LDAKU LDAKA) CO: LIDAK Pharmaceuticals ST: California IN: MTC SU: ERN


AL-EH -- LA015 -- 0355 02/14/92 16:33 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 14, 1992
Words:140
Previous Article:ASPEN WIND ANNOUNCES RECORD DATE CHANGE
Next Article:LEE PHARMACEUTICALS ANNOUNCES FIRST QUARTER RESULTS
Topics:


Related Articles
LIDAK PHARMACEUTICALS REPORTS YEAR-END FINANCIAL RESULTS
LIDAK PHARMACEUTICALS REPORTS YEAR-END FINANCIAL RESULTS
LIDAK PHARMACEUTICALS REPORTS RESULTS
LIDAK PHARMACEUTICALS REPORTS RESULTS
LIDAK PHARMACEUTICALS REPORTS YEAR-END FINANCIAL RESULTS
LIDAK PHARMACEUTICALS ANNOUNCES SECOND QUARTER FINANCIAL RESULTS
LIDAK PHARMACEUTICALS' LEAD DRUG CANDIDATE COMPLETES FIRST PHASE II CLINICAL TRIAL
LIDAK PHARMACEUTICALS AND JAPANESE FIRM COMPLETE $2.0 MILLION PRIVATE EQUITY TRANSACTION
LIDAK PHARMACEUTICALS RECEIVES PATENT ALLOWANCES FOR SCID MOUSE AND FREE FATTY ACID TECHNOLOGIES

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters